Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain

References

• The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176. doi:10.1016/S2468-1253(16)30181-928404132
   PubMed Web of Science ®Google Scholar
• Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74–81. doi:10.1111/j.1478-3231.2008.01934.x
   PubMed Web of Science ®Google Scholar
• Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095–2100.14697814
   PubMed Web of Science ®Google Scholar
• Yoshida H, Tateishi R, Arakawa Y, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut. 2004;53:425–430.14960528
   PubMed Web of Science ®Google Scholar
• Bruno S, Facciotto C. The natural course of HCV infection and the need for treatment. Ann Hepatol. 2008;7:114–119.18626427
   PubMed Web of Science ®Google Scholar
• Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17–35.10895429
   PubMed Web of Science ®Google Scholar
• Ascione A, Tartaglione T, Di Costanzo GG. Natural history of chronic hepatitis C virus infection. Dig Liver Dis. 2007;39(Suppl 1):S4–S7.17936222
   PubMedGoogle Scholar
• Formann E, Steindl-Munda P, Hofer H, et al. Long-term follow-up of chronic hepatitis C patients with sustained virologic response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther. 2006;23:507–511. doi:10.1111/j.1365-2036.2006.02785.x16441471
   PubMed Web of Science ®Google Scholar
• Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology. 2007;50:16–23. doi:10.1159/00009630817164553
   PubMed Web of Science ®Google Scholar
• Annicchiarico BE, Siciliano M, Avolio AW, Grillo RL, Bombardieri G. A 5-year prospective study of the late resolution of chronic hepatitis C after antiviral therapy. Aliment Pharmacol Ther. 2007;25:1039–1046. doi:10.1111/j.1365-2036.2007.03295.x17439504
   PubMed Web of Science ®Google Scholar
• Berden FA, Aaldering BR, Groenewoud H, et al. Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2017;15:349–359. doi:10.1016/j.cgh.2016.10.03427840182
   PubMed Web of Science ®Google Scholar
• Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol. 2012;56:320–325. doi:10.1016/j.jhep.2011.05.03221756855
   PubMed Web of Science ®Google Scholar
• Wu CJ, Roytman MM, Hong LK, et al. Real-world experience with sofosbuvir-based regimens for chronic hepatitis C, including patients with factors previously associated with inferior treatment response. Hawaii J Med Public Health. 2015;74:3–7.
   Google Scholar
• Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65:1861–1870. doi:10.1136/gutjnl-2016-31244427605539
   PubMed Web of Science ®Google Scholar
• Marciano S, Haddad L, Reggiardo MV, et al. Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: a real world study. J Med Virol. 2018 Epub ahead of print. doi:10.1002/jmv.25033
   Web of Science ®Google Scholar
• El-Khayat HR, Kamal EM, El-Sayed MH, et al. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Aliment Pharmacol Ther. 2018 Epub ahead of print. doi:10.1111/apt.14502
   Web of Science ®Google Scholar
• Thi Thu Thuy P, Bunchorntavakul C, Dat HT, et al. Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotypes 1 and 6: real-world experience in Vietnam. Antivir Ther. 2018;23(5):415–423. doi:10.3851/IMP3217.29303482
   PubMed Web of Science ®Google Scholar
• Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47:421–431. doi:10.1111/apt.1442829193226
   PubMed Web of Science ®Google Scholar
• Bichoupan K, Tandon N, Crismale JF, et al. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World J Virol. 2017;6:59–72. doi:10.5501/wjv.v6.i4.5929147645
   PubMedGoogle Scholar
• Buggisch P, Vermehren J, Mauss S, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol. 2018;68(4):663–671. doi:10.1016/j.jhep.2017.11.009 Epub 2017 Nov 11.29133244
   PubMed Web of Science ®Google Scholar
• Abd-Elsalam S, Sharaf-Eldin M, Soliman S, Elfert A, Badawi R, Ahmad YK. Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol. 2018;163:51–56. doi:10.1007/s00705-017-3573-028983675
   PubMed Web of Science ®Google Scholar
• Nagaty A, Abd El-Wahab EW, Kanda T. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt. PLoS One. 2017;12:e0184654. doi:10.1371/journal.pone.018465428981513
   PubMed Web of Science ®Google Scholar
• Ji F, Wang W, Dang S, et al. Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study. Infect Agent Cancer. 2017;12:48. doi:10.1186/s13027-017-0158-128924449
   PubMed Web of Science ®Google Scholar
• Latt NL, Yanny BT, Gharibian D, Gevorkyan R, Sahota AK. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA <6 million: Single center, real world effectiveness and safety. World J Gastroenterol. 2017;23:4759–4766. doi:10.3748/wjg.v23.i26.475928765697
   PubMed Web of Science ®Google Scholar
• Wehmeyer MH, Ingiliz P, Christensen S, et al. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03). J Med Virol. 2018;90:304–312. doi:10.1002/jmv.2490328710853
   PubMed Web of Science ®Google Scholar
• Dalgard O, Weiland O, Noraberg G, et al. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. PLoS One. 2017;12:e0179764. doi:10.1371/journal.pone.017976428704381
   PubMed Web of Science ®Google Scholar
• Curry MP, Tapper EB, Bacon B, et al. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther. 2017;46:540–548. doi:10.1111/apt.1420428691377
   PubMed Web of Science ®Google Scholar
• Johnson SW, Ammirati SR, Hartis CE, et al. Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach. Int J Antimicrob Agents. 2017;49:778–781. doi:10.1016/j.ijantimicag.2017.01.01628389353
   PubMed Web of Science ®Google Scholar
• Maria C, Michael S, Susanne C, et al. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience. Scand J Gastroenterol. 2017;52:585–588. doi:10.1080/00365521.2017.128343928270038
   PubMed Web of Science ®Google Scholar